

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 5, 2012

Commission File Number: 333171722

ACADIA Pharmaceuticals Inc.

(Exact name of small business issuer as specified in its charter)

Delaware

(State or other jurisdiction of incorporation or organization)

061376651

(IRS Employer Identification No.)

3911 Sorrento Valley Blvd, San Diego, California 92121

(Address of principal executive offices)

858-558-2871

(Registrant's Telephone number)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On November 5, 2012, ACADIA Pharmaceuticals Inc. issued a press release announcing its financial results for the third quarter and nine months ended September 30, 2012. A copy of this press release is furnished herewith as Exhibit 99.1. Pursuant to the rule and regulations of the Securities and Exchange Commission, such exhibit and the information set forth therein and in this Item 2.02 have been furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liability under that section nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing regardless of any general incorporation language.

Item 9.01 Financial Statements and Exhibits.

(d) The following exhibit is furnished herewith:

99.1 Press release dated November 5, 2012.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ACADIA Pharmaceuticals Inc.

Date: *November 5, 2012*

By: */s/ Thomas H. Aasen*

*Name: Thomas H. Aasen
Title: Executive Vice President, Chief Financial
Officer and Chief Business Officer*

Exhibit Index

<u>Exhibit No.</u>	<u>Description</u>
EX-99.1	Press release dated November 5, 2012

Contacts:

ACADIA Pharmaceuticals Inc.

Thomas H. Aasen, Executive Vice President,

Chief Financial Officer and Chief Business Officer

(858) 558-2871

ACADIA PHARMACEUTICALS REPORTS
THIRD QUARTER 2012 FINANCIAL RESULTS

SAN DIEGO, CA November 5, 2012 – ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the third quarter ended September 30, 2012.

ACADIA reported a net loss of \$2.4 million, or \$0.04 per common share, for the third quarter of 2012 compared to a net loss of \$5.1 million, or \$0.10 per common share, for the third quarter of 2011. For the nine months ended September 30, 2012, ACADIA reported a net loss of \$14.0 million, or \$0.26 per common share, compared to a net loss of \$17.5 million, or \$0.34 per common share, for the comparable period of 2011.

At September 30, 2012, ACADIA's cash, cash equivalents and investment securities totaled \$23.1 million compared to \$31.0 million at December 31, 2011. ACADIA expects that its current cash resources and anticipated payments from its existing collaborations will be sufficient to fund its operations into the second half of 2013.

“The third quarter was a productive period for ACADIA highlighted by the completion of patient enrollment in the pivotal -020 trial in our Phase III Parkinson's disease psychosis program with pimavanserin,” said Uli Hacksell, Ph.D., ACADIA's Chief Executive Officer. “We remain on track with our -020 trial and look forward to reporting top-line results this month. Meanwhile, preparations are ongoing for the second planned pivotal trial, the -021 trial, and we are continuing to conduct the -015 open-label safety extension trial in this Phase III program. With our pipeline of product candidates, led by pimavanserin, we believe ACADIA is positioned with significant growth potential.”

Revenues increased to \$3.5 million for the third quarter of 2012 compared to \$584,000 for the third quarter of 2011. This increase was primarily due to the recognition of the remaining revenues from ACADIA's collaboration with Meiji Seika Pharma, which was terminated in July 2012. ACADIA recognized \$3.0 million in revenues from this collaboration in the third quarter of 2012, compared to \$112,000 in the third quarter of 2011. ACADIA's remaining revenues were derived from its ongoing agreements with other parties, including its collaborations with Allergan, Inc.

Research and development expenses increased to \$4.4 million for the third quarter of 2012, including \$157,000 in stock-based compensation, from \$4.2 million for the third quarter of 2011, including \$129,000 in stock-based compensation. This increase was primarily due to increased external clinical expenses associated with ACADIA's Phase III program with pimavanserin.

General and administrative expenses totaled \$1.5 million for the third quarter of 2012, including \$331,000 in stock-based compensation, and were comparable to the third quarter of 2011.

Conference Call and Webcast Information

ACADIA management will review its third quarter financial results and development programs via conference call and webcast later today at 5:00 p.m. Eastern Time. The conference call may be accessed by dialing 866-203-3436 for participants in the U.S. or Canada and 617-213-8849 for international callers (reference passcode 61271381). A telephone replay of the conference call may be accessed through November 19, 2012 by dialing 888-286-8010 for callers in the U.S. or Canada and 617-801-6888 for international callers (reference passcode 76643395). The conference call also will be webcast live on ACADIA's website, www.acadia-pharm.com, under the investors section and will be archived there until November 19, 2012.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders. ACADIA has a pipeline of product candidates led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinson's disease psychosis. ACADIA also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. and two preclinical programs directed at Parkinson's disease and other neurological disorders. All of ACADIA's product candidates are small molecules that emanate from discoveries made using its proprietary drug discovery platform. ACADIA maintains a website at www.acadia-pharm.com to which ACADIA regularly posts copies of its press releases as well as additional information and through which interested parties can subscribe to receive email alerts.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements related to the progress and timing of ACADIA's drug discovery and development programs, either alone or with a partner, including clinical trials and the results therefrom, the potential of and the benefits to be derived from product candidates, in each case including pimavanserin, including the timing of results of the -020 trial, the future growth of ACADIA, and the period during which ACADIA's cash resources will be sufficient to fund its operations. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development and commercialization, and collaborations with others, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to ACADIA's annual report on Form 10-K for the year ended December 31, 2011 as well as ACADIA's subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

ACADIA PHARMACEUTICALS INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(Unaudited)

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2012	2011	2012	2011
Collaborative revenues	\$ 3,478	\$ 584	\$ 4,527	\$ 1,479
Operating expenses				
Research and development (includes stock-based compensation of \$157, \$129, \$450 and \$383, respectively)	4,400	4,158	13,893	12,885
General and administrative (includes stock-based compensation of \$331, \$272, \$929 and \$807, respectively)	1,485	1,519	4,701	6,132
Total operating expenses	5,885	5,677	18,594	19,017
Loss from operations	(2,407)	(5,093)	(14,067)	(17,538)
Interest income, net	5	17	28	73
Net loss	\$ (2,402)	\$ (5,076)	\$ (14,039)	\$ (17,465)
Net loss per common share, basic and diluted	\$ (0.04)	\$ (0.10)	\$ (0.26)	\$ (0.34)
Weighted average common shares outstanding, basic and diluted	53,911	52,800	53,262	51,963

ACADIA PHARMACEUTICALS INC.
CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)
(Unaudited)

	<u>September 30, 2012</u>	<u>December 31, 2011⁽¹⁾</u>
Assets		
Cash, cash equivalents and investment securities	\$ 23,058	\$ 31,048
Prepaid expenses, receivables and other current assets	627	901
Total current assets	<u>23,685</u>	<u>31,949</u>
Property and equipment, net, and other assets	65	165
Total assets	<u>\$ 23,750</u>	<u>\$ 32,114</u>
Liabilities and Stockholders' Equity		
Accounts payable, accrued expenses and other current liabilities	\$ 5,820	\$ 5,496
Current portion of deferred revenue	266	669
Total current liabilities	<u>6,086</u>	<u>6,165</u>
Long-term portion of deferred revenue	-	2,587
Total liabilities	<u>6,086</u>	<u>8,752</u>
Stockholders' equity	17,664	23,362
Total liabilities and stockholders' equity	<u>\$ 23,750</u>	<u>\$ 32,114</u>

⁽¹⁾ The condensed consolidated balance sheet at December 31, 2011 has been derived from the audited financial statements at such date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.